Evidence Level
Spirulina is supported by a moderate evidence base, with several systematic reviews and meta-analyses highlighting its potential benefits. A 2018 study by Huang et al. demonstrated that spirulina supplementation can lead to significant reductions in LDL cholesterol (~16%) and triglycerides, as well as improvements in blood pressure and glucose control. The primary bioactive compound, phycocyanin, has been extensively studied for its antioxidant properties and selective COX-2 inhibition (Romay et al., 2003).
Recent research has further explored spirulina's effects on cardiovascular health. A systematic review by Shiri et al. (2025) found that spirulina supplementation significantly lowers systolic (-4.41 mmHg) and diastolic (-2.84 mmHg) blood pressure in adults, while a meta-analysis by Pinto-Leite et al. (2025) highlighted its role as an adjuvant for cardiometabolic risk control. Additionally, spirulina has shown promise in improving glucose homeostasis and reducing inflammation, with Hariri et al. (2026) reporting significant reductions in serum CRP levels.
Despite these findings, limitations remain, including relatively small sample sizes across trials and heterogeneity in spirulina preparations. Most studies use Arthrospira platensis strains, and contamination remains a concern for non-certified products.